Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.
You may also be interested in...
Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year
Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding
Verastem Joins The Public Markets With A Strong IPO
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
Austerity Holds Back VC Investing in European Biotech Companies in 2011
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.